loading...
Allara pairs OB-GYNs, endocrinologists, and dietitians for PCOS, endometriosis, and metabolic conditions – care conventional medicine handles worst.
ENTRY ANGLES
employer hormonal health benefit with measurable ROI · insurance payer partnership based on outcomes data · direct DTC with insurance coverage expansion · GLP-1 and metabolic care integration
VERTICALS
CAPABILITIES
multi-state medical licensing, telemedicine technology, specialist network (OB-GYN, endocrinologist, dietitian), insurance billing and EMR integration, clinical outcomes tracking
ALLARA FOUNDER
“The status quo when it came to women's health needed to change”
PCOS affects an estimated 1 in 10 women of reproductive age. The average time to diagnosis is 2 years; the average number of doctors seen before diagnosis is 3. After diagnosis, fewer than half of patients receive any structured treatment guidance. These aren't rare disease statistics – they're the numbers for the most common hormonal disorder in women of reproductive age. The care infrastructure for hormonal and metabolic conditions in women is structurally inadequate, and it has been for decades.
Rachel Blank was diagnosed with PCOS after years of unexplained symptoms and multiple failed referrals. She built Allara as the coordinated care model she couldn't find: a virtual platform where each patient gets a medical provider – OB-GYN, endocrinologist, or women's health nurse practitioner – alongside a registered dietitian, with integrated lab monitoring, medication management, and insurance coverage in roughly 40 states.
The platform treats the cluster of conditions conventional medicine handles worst: PCOS, endometriosis, thyroid disease, primary ovarian insufficiency, menopause, PMDD, and the overlapping symptoms – fatigue, irregular periods, weight changes, acne – that gynecologists often address in isolation and rarely coordinate. More than 120,000 women are now patients. Allara raised $30M in October 2026, led by Index Ventures and GV, bringing total funding to $75M.
Endometriosis takes an average of 7 to 10 years to diagnose. PCOS is associated with increased lifetime risk for type 2 diabetes, cardiovascular disease, and metabolic syndrome. These are chronic conditions with significant long-term health and economic consequences that a conventional 15-minute OB-GYN visit doesn't address.
What Allara has built is an integrated care model – coordinated specialists, structured lab follow-up, dietary intervention – for a patient population that conventional medicine currently routes through a series of disconnected specialists with no one managing the full picture. The friction in that experience is high enough that most patients abandon care before their condition is well-managed.
The comparison to Maven Clinic ($1B+ valuation) is obvious on the surface. Maven covers the full women's health arc, including pregnancy and parenting. Allara's narrower focus on hormonal and metabolic conditions is actually a harder clinical problem – less reimbursable historically, more chronic, more dependent on dietary and lifestyle intervention alongside medications. That specificity is both the strategic risk and the moat.
120,000 patients with a 98% satisfaction rate and a self-reported 75% improvement rate within weeks is a foundation for an enterprise channel that most women's health platforms haven't built cleanly. Employers already spend on women's health benefits, but those budgets are disproportionately allocated toward fertility and maternity. Hormonal and metabolic conditions generate significant absenteeism – PCOS alone correlates with higher rates of anxiety, depression, and reduced workplace productivity – and that cost is systematically undertracked and unmanaged.
The pitch to a self-insured employer is not "another women's health benefit." It is a specific ROI case: here is the cost per employee year of unmanaged hormonal conditions, here is what our outcomes data shows happens after 6 months on the platform. Maven and Carrot and the fertility-focused players can't make that specific argument. Allara can.
The harder version of this opportunity: insurance. If Allara's outcomes data shows that managed care for PCOS reduces downstream diabetes and cardiovascular risk – which the clinical literature suggests it should – that's an actuarial case for payer coverage at scale. The reimbursement path for chronic condition management is difficult to navigate. But the data infrastructure to make it is being built, one patient record at a time.